NCT05619536View on ClinicalTrials.gov

Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 18, 2022

Primary Completion Date

July 14, 2023

Study Completion Date

July 14, 2023

Conditions
Healthy
Interventions
COMBINATION_PRODUCT

CD388 Injection

CD388 liquid for injection

DRUG

Saline placebo

Sterile normal saline for injection

Trial Locations (1)

90630

Altasciences Clinical Los Angeles, Inc., Cypress

Sponsors

Collaborators (1)

Janssen Pharmaceuticals
All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

Cidara Therapeutics Inc.

INDUSTRY

NCT05619536 - Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects | Biotech Hunter | Biotech Hunter